0000950170-23-047950.txt : 20230913
0000950170-23-047950.hdr.sgml : 20230913
20230913164114
ACCESSION NUMBER: 0000950170-23-047950
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230911
FILED AS OF DATE: 20230913
DATE AS OF CHANGE: 20230913
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sibold William John
CENTRAL INDEX KEY: 0001518611
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33277
FILM NUMBER: 231253181
MAIL ADDRESS:
STREET 1: C/O MADRIGAL PHARMACEUTICALS, INC., FOUR
STREET 2: TOWER BRIDGE, 200 BARR HARBOR DR STE 200
CITY: WEST CONSHOHOCKEN
STATE: PA
ZIP: 19428
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MADRIGAL PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001157601
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BARR HARBOR DRIVE, SUITE 400
CITY: WEST CONSHOHOCKEN
STATE: PA
ZIP: 19428
BUSINESS PHONE: 404-380-9263
MAIL ADDRESS:
STREET 1: 200 BARR HARBOR DRIVE, SUITE 400
CITY: WEST CONSHOHOCKEN
STATE: PA
ZIP: 19428
FORMER COMPANY:
FORMER CONFORMED NAME: SYNTA PHARMACEUTICALS CORP
DATE OF NAME CHANGE: 20010815
4
1
ownership.xml
4
X0508
4
2023-09-11
0001157601
MADRIGAL PHARMACEUTICALS, INC.
MDGL
0001518611
Sibold William John
C/O MADRIGAL PHARMACEUTICALS, INC.
200 BARR HARBOR DRIVE, SUITE 200
WEST CONSHOHOCKEN
PA
19428
true
true
false
false
President and CEO
false
Common Stock
2023-09-11
4
A
false
50000
0
A
50000
D
Performance Restricted Stock Units
2023-09-11
4
A
false
50000
0
A
Common Stock
50000
50000
D
Represents a grant of restricted stock units, which vest as to 25% of the shares on each of September 8, 2024, September 8, 2025, September 8, 2026 and September 8, 2027, provided the Reporting Person continues in service with the Issuer on each such date.
Represents a grant of performance-based restricted stock units, which represent the contingent right to receive a number of shares of the Issuer's common stock that is between 0% and 300% of the target amount of units, depending on the Issuer's achievement of significant sustained stock price appreciation hurdles over a five-year period and which may settle on the 4th, 5th and 6th anniversaries of the grant date, depending on the date of vesting and performance level achieved. The number of shares of common stock reported assumes a target that corresponds to a 100% payout level.
** As attorney-in-fact for Reporting Person
/s/ Brian J. Lynch
2023-09-13